Feeds:
Posts
Comments

Archive for the ‘Hormone therapy’ Category

URO TODAY: Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, but there is no significant benefit for low-risk patients. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: A trial to see whether double hormone therapy for prostate cancer is better than using a single androgen blockade is not expected to report until 2013, so meantime “you are going to have to rely on your own research and a discussion with your doctor”. READ MORE>

Read Full Post »

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

URO TODAY: Higher levels of serum free testosterone are associated with an increased risk of aggressive prostate cancer among older men, say Johns Hopkins researchers. READ MORE>

These data highlight the importance of prospective trials to insure the safety of testosterone-replacement therapy.

Read Full Post »

URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>

Read Full Post »

PHARMACY EUROPE: A new hormone therapy drug for prostate cancer than can be taken once every six months has successfully completed its European registration procedure and will soon be rolled out for use on patients. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Research into a fused gene present in prostate cancer patients shows it is not a helpful marker in predicting the effectiveness of hormone therapy. READ MORE>

We will have to hope that presence of the TMPRSS2-ERG fusion gene can be used to predict something else about prostate cancer — otherwise what we will have is a very common “marker” that has no apparent clinical value.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Intermittent hormone therapy seems to be as effective as combined androgen deprivation, while showing greater tolerability and other quality of life advantages, especially recovery of sexual potency. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Either maximal androgen blockade or hormonal monotherapy are reasonable choices for use in combination with brachytherapy in the management of men with intermediate- or high-risk prostate cancer, a retrospective study finds. READ MORE>

[But]…this study is only a retrospective analysis of database information. A prospective, randomised clinical trial (which has never been carried out as far as we are aware) might demonstrate a different outcome.

Read Full Post »

URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>

Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.

Read Full Post »

« Newer Posts - Older Posts »